Evans D L, McCartney C F, Nemeroff C B, Raft D, Quade D, Golden R N, Haggerty J J, Holmes V, Simon J S, Droba M
Am J Psychiatry. 1986 Apr;143(4):447-52. doi: 10.1176/ajp.143.4.447.
To determine the prevalence of major depression in cancer patients and assess the usefulness of the dexamethasone suppression test (DST) and the thyrotropin-releasing hormone (TRH) stimulation test for diagnosing major depression in these patients, the authors studied 83 women hospitalized for gynecological cancer. Nineteen (23%) had major depression according to DSM-III criteria. The sensitivity and specificity of the DST were 40% and 88%, respectively. No relationship between DST and TRH test results was found. These findings indicate a high prevalence of depression in cancer patients, but further research on these tests in cancer patients is needed; their routine use with cancer patients is premature at this time.
为了确定癌症患者中重度抑郁症的患病率，并评估地塞米松抑制试验（DST）和促甲状腺激素释放激素（TRH）刺激试验在诊断这些患者重度抑郁症方面的有用性，作者对83名因妇科癌症住院的女性进行了研究。根据《精神疾病诊断与统计手册》第三版（DSM-III）标准，19名（23%）患有重度抑郁症。DST的敏感性和特异性分别为40%和88%。未发现DST与TRH试验结果之间存在关联。这些发现表明癌症患者中抑郁症的患病率很高，但需要对癌症患者进行这些试验的进一步研究；目前将其常规用于癌症患者还为时过早。
